Macular Degeneration Trial, Recruiting NCT07515521 Sponsor: Maximilian Pfau Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT07515521
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to provide written consent to participate
  • People of any biological sex or gender identity
  • People aged 18 or older (for the healthy volunteer group) or aged 55 or older (for the group with age-related macular degeneration, known as AMD)
  • People who understand German or English well enough to follow study information and procedures
  • Healthy volunteers: People who have no deposits in the eye called drusen larger than 63 micrometres, and no subretinal drusenoid deposits, in either eye
  • Early AMD group: People whose study eye has drusen larger than 63 micrometres but smaller than 125 micrometres, with no pigmentary (colour or tissue) changes in the eye
  • Intermediate AMD group: People whose study eye has drusen larger than 125 micrometres and/or pigmentary changes in the eye

Who may not be able to join:

  • People with claustrophobia that would affect their ability to tolerate dark-adaptation procedures used in the study
  • People with a known allergy or sensitivity to indocyanine green (a dye used in eye imaging), sodium iodide, or iodine, or who have an overactive thyroid (hyperthyroidism)
  • People who are known to be pregnant
  • People whose study eye has had any eye surgery other than cataract surgery, YAG capsulotomy, or laser retinopexy
  • People whose study eye has an eye disease that the investigators believe could affect visual function testing
  • People with medical conditions or planned operations that could interfere with completing follow-up visits
  • People who are unable to follow study procedures or who do not have sufficient language skills in German or English
  • People who are unable to provide informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 228 287 15505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Maximilian Pfau
Registry
ClinicalTrials.gov
Start date
15 February 2026
Est. completion
15 December 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Rod-Intercept Time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov